drugset / Trial / NCT00039377

Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00039377 ↗

Phase 2 Completed 58 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation works in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation may be an effective treatment for acute lymphoblastic leukemia.

Timeline

Start
2002-04
Primary completion
2012-04
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule — Oral
Background Cyclophosphamide Other / unclassified — Intravenous
Background Cytarabine Small molecule — Intravenous
Background Etoposide Small molecule — Intravenous
Background Leucovorin Small molecule — Intravenous
Background Methotrexate Small molecule — Intrathecal
Background Tacrolimus Small molecule — Intravenous
Background Vincristine Small molecule — Intravenous
Background filgrastim Protein / enzyme biologic — Subcutaneous